148 related articles for article (PubMed ID: 28233452)
1. Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Moritake H; Tanaka S; Nakayama H; Miyamura T; Iwamoto S; Shimada A; Terui K; Saito A; Shiba N; Hayashi Y; Tomizawa D; Taga T; Goto H; Hasegawa D; Horibe K; Mizutani S; Adachi S
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28233452
[No Abstract] [Full Text] [Related]
2. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
5. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
7. Salvaging AML with CLAG: novel option, or more of the same?
Wei A; Teh TC
Leuk Res; 2011 Mar; 35(3):297-8. PubMed ID: 21074270
[No Abstract] [Full Text] [Related]
8. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Longu F; Fozza C; Dessì L; Longinotti M; Bonfigli S; Careddu MG; Coppola L; Giannico DB; Nieddu RM; Podda L; Pardini S; Dore F; Dore S; Sotgiu G
Acta Haematol; 2017; 137(1):15-16. PubMed ID: 27806360
[No Abstract] [Full Text] [Related]
10. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
McCarthy AJ; Pitcher LA; Hann IM; Oakhill A
Med Pediatr Oncol; 1999 Jun; 32(6):411-5. PubMed ID: 10358698
[TBL] [Abstract][Full Text] [Related]
11. [FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):1-2. PubMed ID: 21429391
[No Abstract] [Full Text] [Related]
12. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].
Wang B; Yang B; Dong W; Liu D; Ling Y; Cao X
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):653-5. PubMed ID: 25052613
[No Abstract] [Full Text] [Related]
14. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
15. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
16. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
17. [The clinical comparison of FLAG regimen versus IA regimen for newly diagnosed acute myeloid leukemia].
Yang B; Cao XS; Wang B
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):141-3. PubMed ID: 22730670
[No Abstract] [Full Text] [Related]
18. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G; Kantarjian H; Wang X; Plunkett WK; Gandhi VV; Faderl S; Garcia-Manero G; Ravandi F; Pierce S; Estey EH
Cancer; 2008 Dec; 113(11):3181-5. PubMed ID: 18932257
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Miyawaki S; Kawai Y; Takeshita A; Komatsu N; Usui N; Arai Y; Ishida F; Morii T; Kano Y; Ogura M; Doki N; Ohno R
Int J Hematol; 2007 Nov; 86(4):343-7. PubMed ID: 18055342
[TBL] [Abstract][Full Text] [Related]
20. Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Medeiros BC
Acta Haematol; 2014; 131(4):200-1. PubMed ID: 24296429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
